OptimizeRx (OPRX) Stock Forecast & Price Target

Compare

507 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OPRX Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

OptimizeRx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OPRX Stock 12 Month Forecast

Average Price Target

$16.50

▲(19.74%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for OptimizeRx in the last 3 months. The average price target is $16.50 with a high forecast of $22.00 and a low forecast of $12.50. The average price target represents a 19.74% change from the last price of $13.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","18":"$18","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8,13,18,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,10.590769230769231,11.541538461538462,12.492307692307692,13.443076923076923,14.393846153846155,15.344615384615384,16.295384615384616,17.246153846153845,18.196923076923078,19.14769230769231,20.09846153846154,21.049230769230768,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,10.167692307692308,10.695384615384615,11.223076923076924,11.750769230769231,12.278461538461539,12.806153846153848,13.333846153846155,13.861538461538462,14.38923076923077,14.916923076923077,15.444615384615386,15.972307692307693,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,9.860000000000001,10.08,10.3,10.52,10.74,10.96,11.18,11.4,11.620000000000001,11.84,12.06,12.28,{"y":12.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.42,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.31,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$16.50

Lowest Price Target$12.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$11

Buy

-20.17%

Downside

Reiterated

05/15/25

OptimizeRx receives a moderately strong overall score due to positive revenue trends and operational improvements reflected in recent earnings. However, persistent profitability issues and negative valuation metrics limit the score. Strong technical indicators and strategic leadership changes offer potential for future growth.

Richard BaldryRoth MKM

Roth MKM

$16→$22

Buy

59.65%

Upside

Reiterated

05/13/25

OptimizeRx (OPRX) Gets a Buy from Roth MKM

Eric MartinuzziLake Street

Lake Street

$16

Buy

16.11%

Upside

Reiterated

05/13/25

Lake Street Remains a Buy on OptimizeRx (OPRX)

David GrossmanStifel Nicolaus

Stifel Nicolaus

$8→$12.5

Buy

-9.29%

Downside

Reiterated

05/13/25

OptimizeRx price target raised to $12.50 from $8 at StifelOptimizeRx price target raised to $12.50 from $8 at Stifel

Anderson SchockB.Riley Financial

B.Riley Financial

$13→$18

Buy

30.62%

Upside

Reiterated

05/13/25

OptimizeRx price target raised to $18 from $13 at B. RileyOptimizeRx price target raised to $18 from $13 at B. Riley

Constantine DavidesCitizens JMP

Citizens JMP

$11→$14

Buy

1.60%

Upside

Reiterated

05/13/25

OptimizeRx price target raised to $14 from $11 at Citizens JMPOptimizeRx price target raised to $14 from $11 at Citizens JMP

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/12/25

OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition

Sean DodgeRBC Capital

RBC Capital

Hold

-56.46%

Downside

Downgraded

01/08/25

OptimizeRx (OPRX) was downgraded to a Hold Rating at RBC Capital

Jeffrey GarroStephens

Stephens

$5.5

Hold

-60.09%

Downside

Initiated

12/19/24

OptimizeRx initiated with an Equal Weight at StephensOptimizeRx initiated with an Equal Weight at Stephens

Stephanie DavisBarclays

Barclays

Hold

-63.72%

Downside

Reiterated

11/14/24

Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$11

Buy

-20.17%

Downside

Reiterated

05/15/25

Richard BaldryRoth MKM

Roth MKM

$16→$22

Buy

59.65%

Upside

Reiterated

05/13/25

OptimizeRx (OPRX) Gets a Buy from Roth MKM

Eric MartinuzziLake Street

Lake Street

$16

Buy

16.11%

Upside

Reiterated

05/13/25

Lake Street Remains a Buy on OptimizeRx (OPRX)

David GrossmanStifel Nicolaus

Stifel Nicolaus

$8→$12.5

Buy

-9.29%

Downside

Reiterated

05/13/25

OptimizeRx price target raised to $12.50 from $8 at StifelOptimizeRx price target raised to $12.50 from $8 at Stifel

Anderson SchockB.Riley Financial

B.Riley Financial

$13→$18

Buy

30.62%

Upside

Reiterated

05/13/25

OptimizeRx price target raised to $18 from $13 at B. RileyOptimizeRx price target raised to $18 from $13 at B. Riley

Constantine DavidesCitizens JMP

Citizens JMP

$11→$14

Buy

1.60%

Upside

Reiterated

05/13/25

OptimizeRx price target raised to $14 from $11 at Citizens JMPOptimizeRx price target raised to $14 from $11 at Citizens JMP

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/12/25

OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition

Sean DodgeRBC Capital

RBC Capital

Hold

-56.46%

Downside

Downgraded

01/08/25

OptimizeRx (OPRX) was downgraded to a Hold Rating at RBC Capital

Jeffrey GarroStephens

Stephens

$5.5

Hold

-60.09%

Downside

Initiated

12/19/24

OptimizeRx initiated with an Equal Weight at StephensOptimizeRx initiated with an Equal Weight at Stephens

Stephanie DavisBarclays

Barclays

Hold

-63.72%

Downside

Reiterated

11/14/24

Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OptimizeRx

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+7.46%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +7.46% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+16.95%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +16.95% per trade.

1 Year

Constantine DavidesCitizens JMP

Success Rate

8/10 ratings generated profit

Average Return

+78.11%

reiterated a buy rating 24 days ago

Copying Constantine Davides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +78.11% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+84.92%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +84.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OPRX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OPRX has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OPRX average Analyst price target in the past 3 months is 16.50.

Each month's total comprises the sum of three months' worth of ratings.

OPRX Financial Forecast

OPRX Earnings Forecast

Next quarter’s earnings estimate for OPRX is $0.02 with a range of $0.00 to $0.05. The previous quarter’s EPS was $0.08. OPRX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year OPRX has Outperformed its overall industry.

OPRX Sales Forecast

Next quarter’s sales forecast for OPRX is $22.27M with a range of $22.00M to $22.89M. The previous quarter’s sales results were $21.93M. OPRX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year OPRX has Outperformed its overall industry.

OPRX Stock Forecast FAQ

What is OPRX’s average 12-month price target, according to analysts?

Based on analyst ratings, OptimizeRx Corporation’s 12-month average price target is 16.50.

What is OPRX’s upside potential, based on the analysts’ average price target?

OptimizeRx Corporation has 19.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OPRX a Buy, Sell or Hold?

OptimizeRx Corporation has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is OptimizeRx Corporation’s price target?

The average price target for OptimizeRx Corporation is 16.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $12.50. The average price target represents 19.74% Increase from the current price of $13.78.

What do analysts say about OptimizeRx Corporation?

OptimizeRx Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of OPRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

OptimizeRx (OPRX) Stock Forecast & Price Target

OPRX Analyst Ratings

OPRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering OptimizeRx

OPRX Analyst Recommendation Trends

OPRX Financial Forecast

OPRX Earnings Forecast

OPRX Sales Forecast

OPRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts